Anderson Matheus Pereira da Silva, Dillan Cunha Amaral, Luciano Falcão Carneiro Filho, Kenzo Ogasawara Donato, Ariane Barros Mesquita Cunha, Mariana Letícia de Bastos Maximiano, Bruna Melgaço Batista Alves, Denisse J Mora-Paez, Clarissa Matosinho, Jaime Guedes
{"title":"视网膜母细胞瘤幸存者继发性肿瘤的危险因素：系统的文献综述。","authors":"Anderson Matheus Pereira da Silva, Dillan Cunha Amaral, Luciano Falcão Carneiro Filho, Kenzo Ogasawara Donato, Ariane Barros Mesquita Cunha, Mariana Letícia de Bastos Maximiano, Bruna Melgaço Batista Alves, Denisse J Mora-Paez, Clarissa Matosinho, Jaime Guedes","doi":"10.1080/14737140.2025.2532110","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Retinoblastoma is the most common intraocular malignancy in children. Although survival has improved with multimodal therapy, survivors remain at risk for subsequent malignant neoplasms (SMNs), often due to prior treatments or genetic predisposition. To identify risk factors associated with SMNs in childhood retinoblastoma survivors.</p><p><strong>Methods: </strong>This systematic review followed PRISMA 2020 guidelines and was registered in PROSPERO (CRD420251026103). A comprehensive search was conducted in PubMed, Embase, and Scopus up to January 2025. Observational studies reporting SMNs risk factors were included. Study selection, data extraction, and quality assessment were independently performed by two reviewers.</p><p><strong>Results: </strong>Of 1,640 records, five studies met the inclusion criteria. The main risk factors identified were: radiotherapy, especially linked to bone and soft tissue sarcomas; chemotherapy, notably alkylating agents and anthracyclines; germline RB1 mutations and Li-Fraumeni syndrome; bilateral retinoblastoma; and socioeconomic disparities, with increased SMNs incidence in low- and middle-income countries. One study reported a potential protective role of proton therapy.</p><p><strong>Conclusion: </strong>Radiotherapy, chemotherapy, and genetic predisposition are key risk factors for SMNs in retinoblastoma survivors. Standardized prospective studies are needed to guide prevention strategies and survivor care.</p><p><strong>Registration: </strong>PROSPERO (CRD420251026103).</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1195-1202"},"PeriodicalIF":2.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk factors for secondary neoplasms in retinoblastoma survivors: a systematic literature review.\",\"authors\":\"Anderson Matheus Pereira da Silva, Dillan Cunha Amaral, Luciano Falcão Carneiro Filho, Kenzo Ogasawara Donato, Ariane Barros Mesquita Cunha, Mariana Letícia de Bastos Maximiano, Bruna Melgaço Batista Alves, Denisse J Mora-Paez, Clarissa Matosinho, Jaime Guedes\",\"doi\":\"10.1080/14737140.2025.2532110\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Retinoblastoma is the most common intraocular malignancy in children. Although survival has improved with multimodal therapy, survivors remain at risk for subsequent malignant neoplasms (SMNs), often due to prior treatments or genetic predisposition. To identify risk factors associated with SMNs in childhood retinoblastoma survivors.</p><p><strong>Methods: </strong>This systematic review followed PRISMA 2020 guidelines and was registered in PROSPERO (CRD420251026103). A comprehensive search was conducted in PubMed, Embase, and Scopus up to January 2025. Observational studies reporting SMNs risk factors were included. Study selection, data extraction, and quality assessment were independently performed by two reviewers.</p><p><strong>Results: </strong>Of 1,640 records, five studies met the inclusion criteria. The main risk factors identified were: radiotherapy, especially linked to bone and soft tissue sarcomas; chemotherapy, notably alkylating agents and anthracyclines; germline RB1 mutations and Li-Fraumeni syndrome; bilateral retinoblastoma; and socioeconomic disparities, with increased SMNs incidence in low- and middle-income countries. One study reported a potential protective role of proton therapy.</p><p><strong>Conclusion: </strong>Radiotherapy, chemotherapy, and genetic predisposition are key risk factors for SMNs in retinoblastoma survivors. Standardized prospective studies are needed to guide prevention strategies and survivor care.</p><p><strong>Registration: </strong>PROSPERO (CRD420251026103).</p>\",\"PeriodicalId\":12099,\"journal\":{\"name\":\"Expert Review of Anticancer Therapy\",\"volume\":\" \",\"pages\":\"1195-1202\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Anticancer Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737140.2025.2532110\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2532110","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Risk factors for secondary neoplasms in retinoblastoma survivors: a systematic literature review.
Introduction: Retinoblastoma is the most common intraocular malignancy in children. Although survival has improved with multimodal therapy, survivors remain at risk for subsequent malignant neoplasms (SMNs), often due to prior treatments or genetic predisposition. To identify risk factors associated with SMNs in childhood retinoblastoma survivors.
Methods: This systematic review followed PRISMA 2020 guidelines and was registered in PROSPERO (CRD420251026103). A comprehensive search was conducted in PubMed, Embase, and Scopus up to January 2025. Observational studies reporting SMNs risk factors were included. Study selection, data extraction, and quality assessment were independently performed by two reviewers.
Results: Of 1,640 records, five studies met the inclusion criteria. The main risk factors identified were: radiotherapy, especially linked to bone and soft tissue sarcomas; chemotherapy, notably alkylating agents and anthracyclines; germline RB1 mutations and Li-Fraumeni syndrome; bilateral retinoblastoma; and socioeconomic disparities, with increased SMNs incidence in low- and middle-income countries. One study reported a potential protective role of proton therapy.
Conclusion: Radiotherapy, chemotherapy, and genetic predisposition are key risk factors for SMNs in retinoblastoma survivors. Standardized prospective studies are needed to guide prevention strategies and survivor care.
期刊介绍：
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
